Table 2.
Univariate analysis of the association between clinicopathological characteristics and the BRAFV600E mutation
|
Variables |
BRAFV600E mutation |
P-value |
|
|---|---|---|---|
| Positive (n = 241) | Negative (n = 86) | ||
| Age, years, |
|
|
|
| mean ± SD |
47.63 ± 11.26 |
48.23 ± 10.41 |
0.665 |
| ≥45 |
85 (35.3%) |
32 (37.2%) |
0.747 |
| <45 |
156 (64.7%) |
54 (62.8%) |
|
| Sex, |
|
|
|
| male |
39 (16.2%) |
20 (23.3%) |
0.143 |
| female |
202 (83.8%) |
66 (76.7%) |
|
| Tumour size, cm, |
|
|
|
| mean ± SD, |
1.09 ± 0.72 |
0.89 ± 0.75 |
0.040 |
| ≤1 cm |
147 (61%) |
66 (76.7%) |
0.009 |
| >1 cm |
94 (39%) |
20 (23.3%) |
|
| Extrathyroidal extension, |
|
|
|
| yes |
152 (63.1%) |
40 (46.5%) |
0.007 |
| no |
89 (36.9%) |
46 (53.5%) |
|
| Lymph node metastasis, |
|
|
|
| yes |
110 (47.6%) |
37 (43.5%) |
0.518 |
| no |
121 (52.4%) |
48 (56.5%) |
|
| Central node metastasis, |
|
|
|
| yes |
110 (47.6%) |
35 (41.2%) |
0.308 |
| no |
121 (52.4%) |
50 (58.8%) |
|
| Lateral node metastasis, |
|
|
|
| yes |
19 (8.2%) |
9 (10.6%) |
0.512 |
| no |
212 (91.8%) |
76 (89.4%) |
|
| TNM stage, |
|
|
|
| I |
96 (41.6%) |
41 (48.2%) |
0.138 |
| II |
33 (14.3%) |
7 (8.2%) |
|
| III |
91 (37.7%) |
30 (34.8%) |
|
| IVA |
11 (6.4%) |
7 (8.8%) |
|
| Multifocality, |
|
|
|
| yes |
59 (24.5%) |
23 (26.7%) |
0.678 |
| no |
182 (75.5%) |
63 (73.3%) |
|
| Histology, |
|
|
|
| classic type |
233 (96.7%) |
78 (90.7%) |
0.027 |
| follicular variant |
8 (3.3%) |
8 (3.3%) |
|
| Concurrent Hashimoto’s thyroiditis, |
|
|
|
| yes |
35 (14.5%) |
21 (24.4%) |
0.037 |
| no | 206 (85.5%) | 65 (75.6%) | |
Results are presented as mean ± SD, or number of patients (%). TNM, classification by tumor, nodes and metastases.